Home

CARB-X is accelerating global antibacterial innovation by investing in the development of new antibiotics and other life-saving products to combat the most dangerous drug-resistant bacteria. Our projects represent the world’s largest pre-clinical and early development pipeline of antibiotics and other therapeutics, diagnostics, microbiome, vaccines, and devices.

85+

$million

Invested

30+

company

Projects

7

different

Countries

10

new antibiotic classes in

Pipeline

The Challenge

Accelerate the development of novel antibiotics and other new approaches to address the emergence of drug-resistant superbugs.
Learn More


Spotlight on Science

Bugworks is developing a ‘superdrug’ to treat superbugs.

Learn More

“Antibiotics transformed modern medicine but overuse and inappropriate use have led to dangerous bacteria developing deadly resistance. Drug discovery must go hand-in-hand with concerted action to ensure antibiotics of last resort are reserved for patients where first-line treatments will not work. And we must ensure these treatments are available in all countries for those who need them.”

— Tim Jinks
Head of Drug Resistant Infections
Wellcome Trust

Funders

ASPR
BARDA
WellcomeTrust
NIAID
UK Government

Alliance Partners

Bill and Melinda Gates Foundation

Accelerators

Boston University
RTI
CLSI
MassBio
Broad Institute
DTRA
Wellcome Trust

Events

Events

09.25.18

New York City, NY

The AMR Challenge Launch Event

09.26.18

Boston, MA

Antibacterial Discovery and Development Summit

10.15.18

12057 Berlin, Germany

Grand Challenges Annual Meeting 2018

CARB-X News

  • 09.20.2018  |  CARB-X 2017-18 Annual Report is now online full release

  • 07.31.2018  |  CARB-X funds SciBac to develop a microbe drug that kills C. difficile superbugs full release

  • 07.10.2018  |  CARB-X funds Summit Therapeutics to support development of a new class of antibiotics to treat Gonorrhoea Superbug full release

See All News

In The News

  • 09.05.2018  |  Summit Therapeutics nominates CARB-X-funded SMT-571 as lead clinical candidate for treatment of gonorrhoea full story

  • 07.03.2018  |  MicuRx files IPO on Hong Kong exchange full story

  • 06.19.2018  |  Life sciences sector focus for UK-US event full story

See All News

Sign up for CARB-X news

Get the latest news and announcements from CARB-X.